Transient transfection at large scale for clinical AAV9 vector manufacturing

 

‌AAV9 production in adherent HEK293 cells was scaled from the pilot iCELLis® Nano bioreactor to the large scale iCELLis 500 bioreactor (200 m2 and 333 m2 surface area). A HEK293 cell seed train was utilized, using the Xpansion® 200 bioreactor. Media components were evaluated and replenished as needed throughout the run using the perfusion process of the iCELLis bioreactor. Following a production phase, >1016 vector genomes were isolated from crude harvest of the bioreactor. 

Speaker

Rachel Legmann, PhD

 

 

Transient transfection at large scale for clinical AAV9 vector manufacturing

Learn about scalable, single-use solutions for purification of viral vectors

Watch Todd Sanderson’s video presented during ICST 2020 Virtual event.

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
October 2022
Learning From the Pandemic: Rapid Scale-up of Manufacturing Processes Enabled by Industry Collaboration

Biotech Research & Commercialization Solutions | Pall Corporation webinar series

How Pall and Oxford Biomedica collaborated to develop and scale-up the manufacturing process for the ChAdOx1 COVID-19 vaccine enabling Oxford Biomedica to start manufacturing in less than 6 months.

 

Date & Time:

Thursday October 20, 2022 | 07:00 PST| 10:00 EST | 15:00 BST | 16:00 CET

 

Watch